{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:31:31Z","timestamp":1782711091773,"version":"3.54.5"},"reference-count":70,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T00:00:00Z","timestamp":1477612800000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Generalized motor seizures, usually tonic\u2010clonic, tonic\u2010vibratory, myoclonic or clonic, and stimulus\u2010sensitive\/action myoclonus are typical features of progressive myoclonus epilepsies (PMEs). Despite the introduction of many anticonvulsants, the treatment of these symptoms, particularly myoclonus, remains challenging, due to the incomplete and often transitory effects of most drugs. Moreover, treatment is only symptomatic, since therapy targeting the underlying aetiology for these genetic conditions is in its infancy. Traditional antiepileptic drugs for the treatment of PMEs are valproate, clonazepam, and phenobarbital (or primidone). These drugs may improve the overall performance of PME patients by decreasing their generalized seizures and, to a lesser extent, their myoclonic jerks. Newer drugs which have been shown to be effective include piracetam, levetiracetam, topiramate, zonisamide, and possibly perampanel for Lafora disease. The potential of other drugs (such as L\u2010triptophan and N\u2010acetylcysteine) and procedures (such as vagal and deep brain stimulation) has also been discussed. The available data on the efficacy of drugs are mainly based on small series or anecdotal reports. Two prospective, randomized, double blind studies investigating the novel SV2A ligand, brivaracetam, in genetically confirmed Unverricht\u2010Lundborg patients have been performed with disappointing results. When treating PMEs, particular care should be paid to avoid drugs known to aggravate myoclonus or myoclonic seizures, such as phenytoin, carbamazepine, oxcarbazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, and pregabalin. The emergency treatment of motor status, which often complicates the course of PMEs, consists of intravenous administration of benzodiazepines, valproate, or levetiracetam.<\/jats:p>","DOI":"10.1684\/epd.2016.0861","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T13:24:29Z","timestamp":1564752269000},"source":"Crossref","is-referenced-by-count":44,"title":["Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials"],"prefix":"10.1002","volume":"18","author":[{"given":"Roberto","family":"Michelucci","sequence":"first","affiliation":[{"name":"IRCCS, Institute of Neurological Sciences of Bologna, Unit of Neurology, Bellaria Hospital Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pasini","sequence":"additional","affiliation":[{"name":"IRCCS, Institute of Neurological Sciences of Bologna, Unit of Neurology, Bellaria Hospital Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Riguzzi","sequence":"additional","affiliation":[{"name":"IRCCS, Institute of Neurological Sciences of Bologna, Unit of Neurology, Bellaria Hospital Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Andermann","sequence":"additional","affiliation":[{"name":"Montreal Neurological Hospital &amp; Institute, Neurology &amp; Neurosurgery and Human Genetics McGill University Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetta","family":"K\u00e4lvi\u00e4inen","sequence":"additional","affiliation":[{"name":"Kuopio Epilepsy Center, Department of Neurology Kuopio University Hospital Finland"},{"name":"Centre Saint\u2010Paul \u2010 H\u00f4pital Henri\u2010Gastaut Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Genton","sequence":"additional","affiliation":[{"name":"Centre Saint\u2010Paul \u2010 H\u00f4pital Henri\u2010Gastaut Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00782.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307389501000118"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.11.014"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607313150506"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.01.007"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000345663.71421.1d"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110193.78872.DD"},{"key":"e_1_2_7_9_1","first-page":"36","article-title":"Efficacy of topiramate as add\u2010on therapy in two different types of progressive myoclonic epilepsy","volume":"56","author":"Demir CF","year":"2013","journal-title":"Acta Medica"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10540-007-9041-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21765"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2014.09.003"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90749-3"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.5.781"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1684\/epd.2012.0501","article-title":"Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam","volume":"14","author":"Fernandez\u2010Baca Vaca G","year":"2012","journal-title":"Epileptic Disord"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000077"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.6.1112"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.9.1412"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979237"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00829.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01413.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.6.928"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.5.1264"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510160042008"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110615"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23392"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01546.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13275"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22962"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000271385.85302.55"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000058755.38892.80"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1980.tb04082.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.3.344"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00069-7"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050663"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1981.tb04395.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2004.07.010"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.56902.x"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.11.021"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280129"},{"key":"e_1_2_7_44_1","first-page":"307","article-title":"Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood","volume":"95","author":"Medina MT","year":"2005","journal-title":"Adv Neurol"},{"key":"e_1_2_7_45_1","volume-title":"Epilepsy and movement disorders","author":"Michelucci R","year":"2002"},{"key":"e_1_2_7_46_1","volume-title":"The treatment of epilepsy","author":"Michelucci R","year":"2009"},{"issue":"2","key":"e_1_2_7_47_1","first-page":"S1\u2010158","article-title":"Progressive Myoclonus Epilepsies: State\u2010of\u2010the\u2010Art","volume":"18","author":"Minassian BA","year":"2016","journal-title":"Epileptic Disord"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.02.010"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3144"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.40.6.538"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05479.x"},{"key":"e_1_2_7_52_1","first-page":"253","article-title":"Therapy of myoclonus","volume":"3","author":"Obeso JA","year":"1995","journal-title":"Clin Neurosci"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-006-9039-1"},{"key":"e_1_2_7_54_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pedersen BA","year":"2013","journal-title":"Ann Neurol"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01615.x"},{"key":"e_1_2_7_56_1","first-page":"70","article-title":"Epileptic motor status in progressive myoclonus epilepsy: efficacy of IV phenytoin","volume":"38","author":"Riguzzi P","year":"1997","journal-title":"Epilepsia"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2013.07.003"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70043-0"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00293.x"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-007-0788-3"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb05113.x"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0013-4694(98)00058-3"},{"key":"e_1_2_7_63_1","first-page":"242","article-title":"Zonisamide in the treatment of action myoclonus in progressive myoclonus epilepsies","volume":"40","author":"Tassinari CA","year":"1999","journal-title":"Epilepsia"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199309000-00008"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(99)90097-1"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-002-0001-9"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01166.x"},{"key":"e_1_2_7_68_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1684\/epd.2008.0168","article-title":"Zonisamide for the treatment of myoclonic seizures in progressive myoclonus epilepsy: an open label study","volume":"10","author":"Vossler DG","year":"2008","journal-title":"Epileptic Disord"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00080-6"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02884.x"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00282-0"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1684\/epd.2016.0861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T16:52:34Z","timestamp":1721580754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1684\/epd.2016.0861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":70,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1684\/epd.2016.0861"],"URL":"https:\/\/doi.org\/10.1684\/epd.2016.0861","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}